Abstract
Human papilloma virus (HPV) vaccine was developed to reduce HPV-attributable cancers, external genital warts (EGW), and recurrent respiratory papillomatosis. Adolescent HPV vaccination series completion rates are less than 40% in the United States of America, but up to 80% in Australia and the United Kingdom. Population-based herd immunity requires 80% or greater vaccination series completion rates. Pro-vaccination counseling facilitates increased vaccination rates. Multimodal counseling interventions may increase HPV vaccination series non-completers’ HPV-attributable disease knowledge and HPV-attributable disease prophylaxis (vaccination) acceptance over a brief 14-sentence counseling intervention. An online, 4-group, randomized controlled trial, with 260 or more participants per group, found that parents were more likely to accept HPV vaccination offers for their children than were childless young adults for themselves (68.2% and 52.9%). A combined audiovisual and patient health education handout (PHEH) intervention raised knowledge of HPV vaccination purpose, p = 0.02, and HPV vaccination acceptance for seven items, p < 0.001 to p = 0.023. The audiovisual intervention increased HPV vaccination acceptance for five items, p < 0.001 to p = 0.006. That HPV causes EGW, and that HPV vaccination prevents HPV-attributable diseases were better conveyed by the combined audiovisual and PHEH than the control 14-sentence counseling intervention alone.
Highlights
In the United States (U.S.), approximately 26,900 cases of high-risk human papilloma virus (HPV)-attributed genital and oropharyngeal cancers occur annually [1]
Low-risk non-oncogenic HPV types 6 and 11 are responsible for 96–100% of external genital warts (EGW) that have an incidence of 205 persons per 100,000 persons, affecting up to one million Americans annually [3,4,5]
Quantitative HPV knowledge and HPV vaccination acceptance items were analyzed for the 1109 respondents who completed the survey through the end of the quantitative post-test
Summary
In the United States (U.S.), approximately 26,900 cases of high-risk human papilloma virus (HPV)-attributed genital and oropharyngeal cancers occur annually [1]. Low-risk non-oncogenic HPV types 6 and 11 are responsible for 96–100% of external genital warts (EGW) that have an incidence of 205 persons per 100,000 persons, affecting up to one million Americans annually [3,4,5]. The prevalence of high-risk oncogenic HPV ranges from 16.6 to 65.3%, in American men ages 18 to 44 and American women ages 18 to 35, while low-risk non-oncogenic HPV prevalence ranges from 13.5 to 25.3% [3,8]. All told, this amounts to 75% of Americans experiencing an HPV infection once in their life [9]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.